https://medicine.ouhsc.edu/academic-departments Parent Page: Academic Departments id: 23201 Active Page: Faculty and Staffid:23396

Faculty and Staff

Jian Xu, PhD
Internal Medicine

Jian Xu, PhD

Associate Professor of Medicine


941 Stanton L. Young Blvd.,
Office - BSEB 325
Lab - BSEB 330
Oklahoma City, OK 73104

(405) 271-8001 office ext 48495 lab ext 52604

Jian-Xu@ouhsc.edu


Academic Section(s):

Endocrinology and Diabetes


Education:

  • 1999 - 2002     Doctor of Philosophy, Biochemical Pharmacology, University of Konstanz, Baden-Württemberg, Germany
  • 1985 - 1988     Master of Sciense, Biochemistry, Xinjiang Agricultural University, Urumqi, China
  • 1981 - 1985     Bachelor of Science, Bilogy, Shaani Normal University, Xi'an, China


Fellowship:

  • 2005 - 2008     Postdoctoral Research Fellow, Section of Endocrinology, Diabetes and Metabolism, University of University of Oklahoma Health Sciences Center, Oklahoma City, OK
  • 2004 - 2005     Postdoctoral Research Associate, Department of Surgery, University of Tennessee, Medical Center, Knoxville, TN
  • 2002 - 2003     Postdoctoral Research Associate, Department of Biology, University of Konstanz, Baden-Württemberg, Germany  


Clinical/Research Interests:

Research Interest

Patients with diabetes are at significantly increased risk for both microvascular and cardiovascular adverse events. This is because diabetes promotes disease in nearly all blood vessel types and sizes. Vascular complications are responsible for most of the morbidity, hospitalizations, and mortality in patients with diabetes. Dysregulated endothelial function is one of the major factors contributing to the development of vascular complications in diabetes. By using cell culture and mouse models, our lab explores endothelial regulated pathways that lead to dysmetabolism, a characteristic of metabolic disorders, including diabetes, insulin resistance, and obesity. Our previous research investigated the roles of endothelial regulation on peripheral angiogenesis and dysregulated inflammation in diabetes. As a logical extension to these studies, our current research centers on mechanisms underlying the endothelial regulation of metabolic disorders. Our long-term goal is to translate our bench-side pre-clinical findings to the bedside clinical practice, by providing insights into the development of much-needed management and therapy for these disorders.

  • Mechanisms regulating peripheral angiogenesis in diabetes mellitus
    In diabetes, impaired physiological angiogenesis delays wound healing, exacerbates peripheral limb ischemia, and can even cause cardiac mortality due to a lack of collateral vessel development. However, effective therapies to restore peripheral angiogenesis are elusive. It is unclear how diabetes regulates angiogenesis. We recently found that methylglyoxal (MGO), a metabolite elevated in patients with diabetes, impaired angiogenesis by reducing protein levels of vascular endothelial growth factor receptor 2 (VEGFR2). VEGFR2 is a key angiogenic protein that is downregulated in patients with diabetes and in diabetic mouse models. Our published data showed for the first time that VEGFR2 could be reduced by MGO-activated autophagy in cultured endothelial cells. Building on these data, we seek to understand the role and mechanism of autophagy in diabetic angiogenesis impairment, focusing on autophagy-mediated endothelial cell proliferation, matrix degradation, migration, tube formation, and vessel maturation affected by diabetes. Our goals will be achieved through experiments using genetic and pharmacological approaches in cell culture and mouse models of diabetes. With these approaches, we have identified endothelial autophagy-dependent and independent pathways regulating angiogenesis in diabetes.
     
  • Mechanisms modulating inflammatory response in diabetes mellitus
    Inflammation is a characteristic of both type 1 and type 2 diabetes. Overwhelming evidence demonstrates the association of oxidative stress with vascular inflammatory response in hyperglycemia through mechanisms that are not fully elucidated. Protein degradation by the ubiquitin-proteasome system is central to cell homeostasis and survival. Defects in this process are associated with cancers and neurodegenerative disorders. However, the role of the ubiquitin-proteasome system in diabetes remains largely unknown. Using a proteasome reporter mouse model, we provided the first evidence that early hyperglycemia enhanced 26S proteasome functionality, contributing to elevated endothelial inflammatory response in diabetes. By monitoring 26S proteasome functionality in various mouse models of diabetes, we have identified new endogenous regulators (e.g., eNOS-derived nitric oxide), and new substrates (e.g., O-linked-GlcNAc transferase) that are relevant to vascular inflammation. Consequently, we have begun to understand the significance of protein homeostasis (proteostasis) in diabetes, which could provide insights into the development of therapeutic strategies for diabetes-associated dysregulated inflammation.
     
  • Mechanisms causing metabolic dysfunction in diabetes, obesity, and insulin resistance
    An increasing body of evidence supports the evolving concept that functional interactions between organs/tissues are essential for metabolic homeostasis. Understanding the cause of metabolic dysfunction and diabetes will also require a detailed understanding of how these different tissues and organs work together. The endothelium forms the inner cellular lining of blood vessels by highly metabolically active endothelial cells. The endothelium has long been regarded as an integrated system, like an organ; however, the role and mechanism of endothelium in metabolic homeostasis has just emerged. Our previous studies of the endothelial regulation of cardiovascular complications in diabetes have set a stage on which we will be able to test the role and mechanism of endothelial cross-talk with metabolic organs and tissues. We expect to achieve these goals with genetic and pharmacological approaches in cell co-culture and mouse models of diabetes, obesity, and insulin resistance. Our pilot studies have revealed unexpectedly complex modes of endothelial interactions with metabolic organs/tissues, depending, at least in part, on duration of disease (e.g., diabetes and/or obesity) and locations of impacts (e.g., fat, liver, or skeletal muscle), which warrants further investigations of their clinical implication and translation.


Select Publications:

Wu H, Norton V, Cui K, Zhu B, Bhattacharjee S, Lu YW, Wang BB, Shan D, Wong S, Dong Y, Chan SL, Cowan D, Xu, J, Bielenberg D, Zhou C, Chen H. Diabetes and its cardiovascular complications: comprehensive network and systematic analyses. Frontiers in Cardiovascular Medicine. 2022 Feb 17; 9:841928. PMID: 35252405. PMCID: PMC8891533

Li M, Qian M, Kyler K, Xu, J*. Adipose tissue-endothelial cell interactions in obesity-induced endothelial dysfunction. Frontiers in Cardiovascular Medicine. 2021 Jul 1; 8:681581. PMID: 34277732. PMCID: PMC8282205

Li M, Qian M, Kyler K, Xu, J*. Endothelial–vascular smooth muscle cells interactions in atherosclerosis. Frontiers in Cardiovascular Medicine. 2018 Oct 23; 5:151.PMID: 30406116. PMCID: PMC6207093

Rao G, Nkepang G, Xu J, Yari H, Houson H, Awasthi V. Ubiquitin receptor RPN13 mediates the inhibitory interaction of diphenyldihaloketones CLEFMA and EF24 with the 26S proteasome. Frontiers in Chemistry (Chemical Biology). 2018: 6 (392), 1-13. PMID: 30280096. PMCID: PMC6153970.

Wu H, Rahman H, Dong Y, Liu X, Lee Y, Wen A, To K, Xiao L, Yang W, Birsner A, Bazinet L, Wong S, Song K, Brophy M, Mahamud M, Chang B, Cai X, Pasula S, Kwak S, Xu J, Bischoff J, Bielenberg D, Dixon, BJ, D’Amato JR, Srinivasan SR, Chen H. Epsin deficiency promotes lymphangiogenesis through regulation of VEGFR3 degradation in diabetes. Journal of Clinical Investigation. 2018: 128(9), 4025-4043. PMID: 30102256. PMCID: PMC6118634

Li M, Qian M, Xu J*. Vascular endothelial regulation of obesity-associated insulin resistance. Frontiers in Cardiovascular Medicine. 2017; Aug 9; 4:51. PMID: 28848738 PMCID: PMC5552760

Klionsky DJ, Abdelmohsen K, Abe A, Abeliovich H, Arozena AA, Adler SG, Xu J, Ziparo E, Zois CE, Zoladek T, Zong WX, Zorzano A, Zughaier SM. Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (3rd edition). Autophagy. 2016; 12(1) 1-222. PMID: 26799652

Xing J, Liu H, Yang H, Chen R, Chen Y, Xu J*. Upregulation of Unc-51-like kinase 1 by nitric oxide stabilizes SIRT1, independent of autophagy. PLoS One 2014, 9(12): e116165. PMID: 25541949. PMCID: PMC4277463

Liu H, Wang Z, Yu S and Xu J*. Proteasomal degradation of O-GlcNAc transferase elevates hypoxia-induced vascular endothelial inflammatory response. Cardiovasc. Res. 2014. 103(1):131-9.  PMID: 24788415. PMCID: PMC4133591

Liu H, Yu S, Zhang H and Xu J*. Identification of nitric oxide as an endogenous inhibitor of 26S proteasomes in vascular endothelial cells. PLoS ONE. 2014 ;9(5): e98486. PMID: 24853093. PMCID: PMC4031199

Li Y, Liu H, Xu QS, Du YG and Xu J*. Chitosan oligosaccharides block LPS-induced O-GlcNAcylation of NF-κB and endothelial inflammatory response. Carbohydrate Polymer. 2014; 99:568-78. PMID: 24274545. PMCID: PMC3843148

Liu H, Yu S, Zhang H and Xu J*. Angiogenesis impairment in diabetes: Role of methylglyoxal-induced receptor for advanced glycation endproducts, autophagy and vascular endothelial growth factor receptor 2. PLoS ONE. 2012. 7(10): e46720. PMID: 23056421. PMCID: PMC3463541

Liu H, Yu S, Xu W and Xu J*. Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012. 32 (9):2131-2140. PMID: 22772755. PMCID: PMC3432586